生物谷援引美通社北卡羅來納州達勒姆7月2日電：對患有胃腸道間質瘤 (GIST) 的罕見癌癥患者來說,，伊馬替尼 (Gleevec(R)) 藥物的使用已經(jīng)較先前的療法產(chǎn)生了具有革命性意義的改進,。然而，盡管采用了伊馬替尼,，在有些患者中,，癌細胞還是會立即或在出現(xiàn)初始反應后繼續(xù)增長。The Oncologist6月期的一篇文章關注了近期對伊馬替尼抗藥性（包括可能在不久的將來開展對 GIST 個性化治療的結果）原因的研究,。
根據(jù)新的發(fā)現(xiàn),，Stefan Sleijfer 博士及其在荷蘭鹿特丹伊拉茲馬斯大學醫(yī)學中心 (Erasmus University Medical Center) 的同事的論文得出結論：“在治療受難以用伊馬替尼治療疾病時已經(jīng)采取了幾種策略，可以預測,，在這一發(fā)現(xiàn)的基礎上，將開發(fā)出其他積極的系統(tǒng)療法,。”
胃腸道間質瘤是罕見的胃腸道癌癥,。如果發(fā)現(xiàn)得及時，該疾病可以通過手術進行治療,。過去,，則對更晚期的 GIST 病例進行標準化療。盡管如此,，治療結果卻沒有患有其他類型癌癥的患者的治療那么理想,。
原始出處:
The Oncologist, Vol. 12, No. 6, 719-726, June 2007; doi:10.1634/theoncologist.12-6-719
Improved Insight into Resistance Mechanisms to Imatinib in Gastrointestinal Stromal Tumors: A Basis for Novel Approaches and Individualization of Treatment
Stefan Sleijfer, Erik Wiemer, Caroline Seynaeve, Jaap Verweij
Department of Medical Oncology, Erasmus University Medical Centre, Daniel den Hoed Cancer Centre, Rotterdam, The Netherlands
Key Words. GIST • Imatinib • Resistance • Sunitinib
Correspondence: Stefan Sleijfer, M.D., Ph.D. Department of Medical Oncology, Erasmus University Medical Centre, Daniel den Hoed Cancer Centre, Groene Hilledijk 301, 3075 EA Rotterdam, The Netherlands. Telephone: 31-010-4391733; Fax: 31-010-4391003; e-mail: [email protected]
Gastrointestinal stromal tumor (GIST) is one of the first solid tumor types in which a tyrosine kinase inhibitor, imatinib, has become standard of care for patients with advanced disease. Although imatinib yields antitumor activity in the vast majority of patients, it is likely that all patients eventually experience progressive disease given enough time. In recent years, major progress has been made in the elucidation of mechanisms conferring resistance to imatinib that result in progressive disease. Insight into these resistance mechanisms has already resulted in the availability of strategies that can be applied in cases of progressive disease and it is likely that more approaches will be defined in the next years. Additionally, it can be anticipated that in the near future treatment will be guided according to factors determining sensitivity to imatinib. This review focuses on the factors inducing imatinib resistance that have been elucidated so far, the currently available and potential novel treatment options for patients with progressive disease, and how insight into resistance mechanisms may allow individualized treatment in the near future for patients with advanced GISTs.
Disclosure of potential conflicts of interest is found at the end of this article.
